The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Key clinical outcomes for evaluating treatment success in myelofibrosis
Francesco Passamonti, MD, University of Milan, Milan, Italy, discusses key outcomes clinicians and researchers should focus on when evaluating treatment success in patients with myelofibrosis. Dr Passamonti highlights evidence that reducing clones, such as JAK2, has disease-modifying potential and can lead to improved progression-free survival, and that modifying cytokines can have an advantage in terms of spleen reduction, symptom control, and overall survival. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
